These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2347058)

  • 41. High-dose epirubicin in combination with cyclophosphamide (HD-EC) in advanced breast cancer: final results of a dose finding study and phase II trial.
    Marschner N; Nagel GA; Beyer JH; Adler M; Ammon A
    Onkologie; 1990 Aug; 13(4):272-8. PubMed ID: 2234780
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epirubicin and ifosfamide in advanced soft tissue sarcomas.
    Frustaci S; Foladore S; Buonadonna A; De Paoli A; Crivellari D; Carbone A; Sorio R; Morassut S; Monfardini S
    Ann Oncol; 1993 Sep; 4(8):669-72. PubMed ID: 8240997
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
    Piccart MJ; Di Leo A; Beauduin M; Vindevoghel A; Michel J; Focan C; Tagnon A; Ries F; Gobert P; Finet C; Closon-Dejardin MT; Dufrane JP; Kerger J; Liebens F; Beauvois S; Bartholomeus S; Dolci S; Lobelle JP; Paesmans M; Nogaret JM
    J Clin Oncol; 2001 Jun; 19(12):3103-10. PubMed ID: 11408507
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Lisboa BW; Untch M; Kühnle H; Jänicke F; Meerpohl HG; Lindner C; Konecny G; Hecker D; Diergarten K
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S13-6. PubMed ID: 9071334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
    de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M
    Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
    Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
    Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma].
    Huang HQ; Zhou ZM; Li YH; Jiang WQ; He YJ; Teng XY; Guan ZZ
    Ai Zheng; 2002 Apr; 21(4):409-11. PubMed ID: 12452022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study.
    Palumbo R; Neumaier C; Cosso M; Bertero G; Raffo P; Spadini N; Valente S; Villani G; Pastorino M; Toma S
    Eur J Cancer; 1999 Jan; 35(1):66-72. PubMed ID: 10211090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer].
    Shinagawa K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Fukutani H; Tabata M; Hirano A; Mizunuma N
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3277-81. PubMed ID: 3143311
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
    Graziano SL; Herndon JE; Richards F; DiFino S; Modeas C; Duggan DB; Green MR
    Cancer; 1993 Jul; 72(1):62-8. PubMed ID: 8389667
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dose- intensified, preoperative and adjuvant chemotherapy in patients with T3- and T4- breast cancer: toxicity, clinical and pathological remission.
    Blohmer JU; Paepke S; Kissner L; Elling D; Fleige B; Grineisen Y; Lichtenegger W
    Zentralbl Gynakol; 1999; 121(11):522-5. PubMed ID: 10612219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
    Capotorto AM; Pavesi L; Pedrazzoli P; Da Prada GA; Zamagni C; Massidda B; Farris A; Martoni A; Lelli G; Robustelli della Cuna G
    J Chemother; 2003 Apr; 15(2):184-91. PubMed ID: 12797397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
    Loeffler TM; Weber FW; Hausamen TU
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S125-8. PubMed ID: 1795000
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
    Pronk LC; Schrijvers D; Schellens JH; de Bruijn EA; Planting AS; Locci-Tonelli D; Groult V; Verweij J; van Oosterom AT
    Semin Oncol; 1998 Feb; 25(1 Suppl 2):23-8. PubMed ID: 9535208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epirubicin and ifosfamide in metastatic breast cancer.
    Becher R; Kloke O; Hayungs J; Hartwich G; Bartels H; Szanto J; Wolf E; Illiger HJ; Halabi S; Rieche K; Hering KG; Ohl S; DeDycker R; Huhn R; Fischedick AR; Höfeler H; Pielken HJ; Hawig I; Hirche H; Seeber S
    Semin Oncol; 1996 Jun; 23(3 Suppl 7):28-33. PubMed ID: 8711499
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prospective evaluation of chronic cardiotoxicity due to high-dose epirubicin or combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Havsteen H; Brynjolf I; Svahn T; Dombernowsky P; Godtfredsen J; Munck O
    Cancer Chemother Pharmacol; 1989; 23(2):101-4. PubMed ID: 2910506
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.
    Manegold C; Worst P; Bickel J; Schmid H; Drings P; Kaufmann M
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S87-90. PubMed ID: 2112056
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M; Erturk D
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study.
    Cervellino JC; Araujo CE; Pirisi C; Francia A; Cerruti R
    Oncology; 1991; 48(2):89-92. PubMed ID: 1900124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.